139 related articles for article (PubMed ID: 12699361)
1. Subunit protein vaccines: theoretical and practical considerations for HIV-1.
Cho MW
Curr Mol Med; 2003 May; 3(3):243-63. PubMed ID: 12699361
[TBL] [Abstract][Full Text] [Related]
2. Criteria for selection of HIV vaccine candidates--general principles.
Ensoli B
Microbes Infect; 2005 Nov; 7(14):1433-5. PubMed ID: 16213181
[TBL] [Abstract][Full Text] [Related]
3. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
4. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.
Devadas K; Boykins RA; Hewlett IK; Wood OL; Clouse KA; Yamada KM; Dhawan S
Peptides; 2007 Mar; 28(3):496-504. PubMed ID: 17188401
[TBL] [Abstract][Full Text] [Related]
6. Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env.
Ensoli B; Cafaro A; Caputo A; Fiorelli V; Ensoli F; Gavioli R; Ferrantelli F; Cara A; Titti F; Magnani M
Microbes Infect; 2005 Nov; 7(14):1392-9. PubMed ID: 16243561
[TBL] [Abstract][Full Text] [Related]
7. Ability to generate synthetic peptides that immunologically mimic HIV-1 tat regulatory protein.
Biquard JM; M'Bika JP; Krsmanovic V; Achour A
AIDS; 2003 Sep; 17(13):2001-2. PubMed ID: 12960840
[No Abstract] [Full Text] [Related]
8. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
[TBL] [Abstract][Full Text] [Related]
9. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.
Rolland M; Jensen MA; Nickle DC; Yan J; Learn GH; Heath L; Weiner D; Mullins JI
J Virol; 2007 Aug; 81(16):8507-14. PubMed ID: 17537854
[TBL] [Abstract][Full Text] [Related]
10. The rationale behind a vaccine based on multiple HIV antigens.
Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 Tat vaccines.
Ensoli B; Cafaro A
Virus Res; 2002 Jan; 82(1-2):91-101. PubMed ID: 11885958
[No Abstract] [Full Text] [Related]
12. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic HIV Peptide Vaccine.
Fomsgaard A
Methods Mol Biol; 2015; 1348():351-7. PubMed ID: 26424286
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 Tat-based vaccines: from basic science to clinical trials.
Fanales-Belasio E; Cafaro A; Cara A; Negri DR; Fiorelli V; Butto S; Moretti S; Maggiorella MT; Baroncelli S; Michelini Z; Tripiciano A; Sernicola L; Scoglio A; Borsetti A; Ridolfi B; Bona R; Ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Vardas E; Magnani M; Laguardia E; Caputo A; Titti F; Ensoli B
DNA Cell Biol; 2002 Sep; 21(9):599-610. PubMed ID: 12396602
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of HIV-1 Tat-based vaccines.
Caputo A; Gavioli R; Ensoli B
Curr HIV Res; 2004 Oct; 2(4):357-76. PubMed ID: 15544457
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the development of an HIV-1 vaccine.
Barouch DH
Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
[TBL] [Abstract][Full Text] [Related]
17. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
18. The effects of CpG-ODNs and Chitosan adjuvants on the elicitation of immune responses induced by the HIV-1-Tat-based candidate vaccines in mice.
Alipour S; Mahdavi A; Abdoli A
Pathog Dis; 2017 Mar; 75(2):. PubMed ID: 28175274
[TBL] [Abstract][Full Text] [Related]
19. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
[TBL] [Abstract][Full Text] [Related]
20. The basis for HIV immunotherapeutic vaccines.
Peters BS
Vaccine; 2001 Dec; 20(5-6):688-705. PubMed ID: 11738732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
